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Binding characteristics of [3H]BAY K 8644, a new class of pharmacologically potent compounds, the 
calcium channel activating dihydropyridines (DHP), were demonstrated in cultured myocardial cells. 
[3H]BAY K 8644 exhibited reversible and saturable binding to myocytes, and specific binding was 
Ca’+-dependent. The equilibrium dissociation constant, Kd, was 35.2 nM, and maximal binding capacity, 
B max, was 1.07 pmol/mg protein. Binding of the 3H-ligand was highly specific for various potently 
displacing DHP derivatives (either the calcium channel activating BAY K 8644, or the Ca2+ entry blockers 
of the nifedipine type) with inhibition constants (Ki values) in the nanomolar range. BAY K 8644, on the 
other hand, showed very low affinity to other receptors tested in brain and heart membranes. Displacement 
potency of BAY K 8644 correlated well with data of the functional pharmacology; e.g., the enhanced 
myocardial contractility. Results from competition studies using [3H]BAY K 8644 and [3H]nimodipine 
support the conclusion that both the channel activating and inhibiting DHP structures interact with the 
same specific receptor site that might be associated with the putative Ca’+-channel. 
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1. INTRODUCTION 
Calcium ions play a central role in myocardial 
contractility, and it is generally accepted that the 
intracellular levels of free Ca2+ trigger such impor- 
tant cell biological processes as the excitation- 
confraction coupling or the positive inotropy. 
Drugs that enhance Ca2+ influx, e.g., adrenaline 
[l] or theophylline (see [2]), are known to exert 
Abbreviations: BBS, balanced salt solution; DMEM, 
Dulbecco’s modified Eagle’s medium; Hepes, 
N-2-hydroxyethylpiperazine N’-2-ethanesulfonic acid; 
BAY K 8644, methyl 1,4-dihydro-2,6-dimethyl-3-nitro- 
4-(2-trifluoromethylphenyl)-pyridine-5-carboxylate 
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cardiostimulatory effects. On the other hand, the 
dihydropyridines, e.g., nifedipine, nimodipine, 
nisoldipine, reduce Ca2+ entry into the cell and 
have been termed ‘calcium antagonists’ [3]; they 
are of considerable potential in the therapy of 
hypertension and many cardiovascular disorders 
(see 14,511. 
In 1981, high affinity binding for 
dihydropyridines (DHPs) was identified for the 
first time in cardiac membranes [6], and subse- 
quently confirmed also in other tissues [7-lo]. 
Recently, the existence of a functional receptor site 
for the DHP structure has been reported with the 
Ca2+ entry blocker [3H]nimodipine [l 11. The pre- 
sent report documents binding characteristics of 
[3H]BAY K 8644, a novel type of DHP that has 
been ascribed to exert Ca2+ channel activating ef- 
fects [12], and further substantiates the regulatory 
significance of the DHP receptor in modulating 
transmembrane Ca2+ currents. 
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2. MATERIALS AND METHODS 
[3H]BAY K 8644 (87 Ci/mmol) and [3H]nimo- 
dipine (150 Ci/mmol) were synthesized by New 
England Nuclear (Boston, MA) and their purity 
was monitored by thin-layer radiochromatography. 
The ligands were stored in the dark at - 30°C 
under nitrogen gas to prevent radiolysis and oxida- 
tion. 
Pregnant albino rats (280-350 g) were received 
20 days after mating (Wistar, Lippische Versuchs- 
tierzucht, Extertal, FRG). They were killed by cer- 
vical dislocation and foetuses were removed and 
cleaned. Embryonic hearts were pooled in buffered 
saline solution (BSS) containing glucose (5.5 mM) 
and foetal calf serum (FCS, lo%), minced, and 
cell suspensions were prepared by a multiple-cycle 
trypsinization method [ 13- 151. After complete dis- 
aggregation, myocytes were maintained as mono- 
layer cultures in Dulbecco’s MEM containing FCS 
(2OOro), tryptose phosphate broth (TPB, lo%), 
Hepes (20 mM), glutamine (6.8 mM) and 8-bromo- 
cyclic-AMP (0.1 mM [ 161) using an atmosphere of 
COJair (1:19). After 72 h in culture myocardial 
cells were removed from tissue culture flasks by 
trypsinization (O.OSOro), washed with BSS and seed- 
ed onto 24-well tissue culture clusters of costar 
(Greiner, Ntirtingen, FRG) at a density of 1.5 x 
10’ cells/well. After the 4-h period of attachment 
the medium was flicked off, and cell cultures were 
washed twice with cold NaCl (0.9%) containing 2 
mM EGTA. Membrane fractions from rat brain 
cortices were prepared as in [ll]. 
Binding assays were performed essentially as in 
[l l] under strict sodium light. In a final volume of 
0.25 ml, cells were incubated at 37°C in Tyrode 
solution containing 1 mM CaC12, the indicated 
concentration of radioligands and various ad- 
ditives; e.g., drugs as displacers. After the in- 
dicated time intervals, the reaction was terminated 
by rapidly aspirating the incubation fluid and 
washing the monolayers with 3 ml of ice-cold NaCl 
(0.9%) solution. Cellular radioactivity was then 
solubilized by trypsinization (O.OSO/‘o, 10 min, 
37’C), and measured by conventional iquid scin- 
tillation spectrophotometry. Protein was measured 
as in [17] with serum albumin as the standard. 
Data were calculated and plotted according to 
Scatchard, and displacement experiments were 
analyzed with computer programmes. 
3. RESULTS AND DISCUSSION 
[3H]BAY K 8644 interacted with membrane 
fractions from heart and brain; however, specific 
binding in these preparations was low and ranged 
between 15-30070, only. Thus, intact myocardial 
cells in monolayer cultures were used for binding 
studies. As shown by radiochromatography 
[3H]BAY K 8644 remained stable under all ex- 
perimental conditions reported here. Specific bind- 
ing to myocytes was linearly proportional to cell 
density up to 5 x 10’ cells/well (approx. 100 pg of 
protein); thus, all binding studies were carried out 
in the linear range using 1.5 x 10’ cells/well. Total 
and non-specific binding were corrected in each ex- 
perimental value for the amount of radioactivity 
adherent o the plastic surface. Addition of 10 PM 
of BAY K 8644 to binding assays displaced 
60-75070 of the total [3H]BAY K 8644 binding. 
[3H]BAY K 8644 bound reversibly and saturably 
to cultured myocardial cells, and sufficient specific 
binding for kinetic analyses was dependent on the 
extracellular Ca’ + concentration used. The 
specific binding of [3H]BAY K 8644 to cultured 
myocytes reached steady-state values rapidly and 
showed maximal binding after about 2-3 min 
(fig.1). The time-course of association yielded a 
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Fig. 1. Time course of 13H]BAY K 8644 specific binding 
demonstrating reversibility in pulse-chase experiments. 
The figure shows a representative experiment carried out 
with cultured myocytes in the presence (1 mM) and 
absence of CaC12 in the binding assay. After linear 
transformation of the data from the association and dis- 
sociation (arrow: addition of 10 PM of BAY K 8644) 
reaction, kinetic constants (insets, r>0.966) were 
estimated by the &bs method [18]. 
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rate constant Kobs [18] of 0.611 min-’ (r = 0.966) 
in the presence of 1 mM CaClz. In the absence of 
extracellular CaClz, binding of, [3H]BAY K 8644 
was reduced by about 60-70% and association oc- 
curred considerably slower with rate constants of 
0.337 mine1 (r = 0.997), substantiating the ef- 
ficacy of Ca2+ in accelerating [3H]BAY K 8644 
binding to the receptor site in beating myocytes. 
The specific binding of [3H]BAY K 8644 was 
saturable and plateaus were achieved between 80 
and 100 nM of radioligand (fig.2). Scatchard 
analyses of the saturation isotherms (fig.1, inset) 
revealed a straight line indicating the presence of a 
single binding site. The equilibrium dissociation 
constant Kd was 35.2 + 6.53 nM (r>0.93; n=4), 
with a number of binding sites (density) Bmax, 
equivalent to 1.07 .f 0.122 pmol/mg protein 
(rB0.93; n=4). Hill plots of the [3H]BAY K 8644 
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Fig. 2. Saturation isotherm of [3H]BAY K 8644 binding 
to cultured myocytes. [3H]BAY K 8644, 4.2-120.3 nM, 
was incubated at least in triplicate with or without excess 
unlabelled BAY K 8644. Specific binding (0, pmol/mg 
protein), defined as conditions under which non-specific 
binding remains linear, was calculated as the difference 
between total binding and that not displaced by excess 
(10 PM) BAY K 8644. The latter (non-specific binding) 
ranged between 25-40% (see text). Inset: Scatchard 
analysis of specific binding data (B, bound ligand; F, 
free ligand) revealed linearity and indicated one binding 
site with an equilibrium dissociation constant Kd = 24.3 
nM (reciprocal of the slope value) and maximal binding 
(Bmax) of 1.23 pmol/mg protein (r = 0.960, intercept on 
abscissa). The experiment was repeated several times 
with different myocyte preparations and yielded iden- 
tical results (rD0.95). 
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Fig. 3. Displacement experiments using [‘HIBAY K 8644 
(< 30 nM) and the unlabelled compound in salt solution 
(Tyrode) and serum containing tissue culture medium 
(Dulbecco’s MEM). Total binding to cultured myocytes 
is plotted against -1ogro of BAY K 8644 as displacer 
concentration (M). Total binding of [3H]BAY K 8644 
(set 100%) was reduced by 20-30% in the serum contain- 
ing Dulbecco’s MEM. Data are the means k SE of 3 ex- 
periments using different myocyte cultures. 
saturation isotherm (not shown) gave slopes be- 
tween 0.96 and 1.15 (r> 0.93) indicating absence of 
cooperativity. 
The pharmacological profile of [3H]BAY K 8644 
binding sites was evaluated by displacement studies 
under various experimental conditions. Fig. 3 
shows an example of such a displacement experi- 
ment with unlabelled BAY K 8644 performed in 
Tyrode solution and Dulbecco’s MEM. BAY K 
8644 in salt solution displayed much higher affinity 
for the DHP binding site than in nutritional 
medium that generally reduced total [3H]BAY K 
8644 binding by about 20-30% suggesting interac- 
tion of the radioligand with additional components 
in the serum containing medium. Similarly, shifts 
in the competition curves, and concomitantly 
changes in the Ki or ZC~O values toward’higher af- 
finities of l-2 orders of magnitude were obtained 
by increasing the Ca2 + concentration from 0.45 
mM up to 3.6 mM in the extracellular fluid. 
Calcium channel inhibiting agents with DHP 
structure, e.g., nifedipine, nimodipine or nisol- 
90 
Volume 167, number 1 FEBS LETTERS February 1984 
&pine, displaced [3H]BAY K 8644 binding to 
myocytes with inhibitory characteristics (Kt, or 
I& values) close to those reported recently using 
[3H]nimodipine as the radioligand [ 111. 
The structural specificity of the calcium channel 
activating BAY K 8644 for the DHP receptor is ap- 
parent in the lack of affinity to various receptors 
measured in brain and heart membranes (table 1). 
Interaction of BAY K 8644, and certain other 
DHP derivatives with 10 different receptors - 
muscarinic cholinergic-, CY~-, (YZ-, and&adrenergic-, 
benzodiazepine-, dopamine-, y-aminobutyric 
acid-, histamine-, opiate- and serotonin receptors 
- revealed low or even very low displacement 
activity. 
Table 1 
The interaction of the calcium channel ac- 
tivating BAY K 8644 with the Ca2+ entry blocker 
[3H]nimodipine (fig.4) revealed displacement ac- 
tivity of Ki = 30 nM. The affinities of the potent 
channel inhibitors nimodipine and nifedipine, on 
the other hand, were just slightly more affine by 
about one order of magnitude (NIM, 1.4 nM; NIF, 
7.0 nM [ll]). Thus, data substantiate the high 
specificity of the DHP receptor for dihydro- 
pyridine derivatives of both the channel activating 
and inhibiting structures. Slopes of the Hill plot 
from competition studies with [3H]nimodipine 
yielded identical results as found with [3H]BAY K 
8644 (see above). Interestingly, compounds known 
to increase intracellular Ca*+ concentration - a 
prerequisite for excitation-contraction coupling - 
e.g., strophantin, exhibited no affinity to the DHP 
receptor (fig.4). 
Interaction of the calcium channel activating dihydro- 
pyridine BAY K 8644 with various receptors measured in 
Binding and displacement characteristics of 
[3H]BAY K 8644 in cultured myocardial cells, e.g., 
membrane preparations from brain and heart 
I&, values (M) of drugs on brain receptors 
) [3H]-NIMOOlPINE 
Receptor and radioligand BAY K 8644 
Dopamine-2, [3H]spiroperidol 1.9 f 0.37 x 1o-4 
ACh-muscarinic, [3H]QNB >10-2 
Alpha-l, (3H]prazosin 2.7 + 0.60 x 1O-5 
Alpha-2, [3H]clonidine 4.9 * 2.5 x 1o-4 
Beta, [3H]dihydroalprenolo1 >10-2 
Serotonin, [‘Hlserotonin 8.1 f 7.1 x 1O-4 
Histamine, [3H]cimetidine > 1o-2 
GABA, [3H]muscimol > 1o-2 
Diazepam, [3H]diazepam 1.4 + 0.22 x 1o-4 
Opiate p, [3H]naloxone 6.0 + 0.54 x lo-’ 
loo- 
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NIFEDIPINE 
I& values (M) of drugs on heart receptors 
Receptor and radioligand BAY K 8644 
ACh-muscarinic, [3H]QNB 3.6 + 1.4 x 1O-4 
Alpha-l, [3H]prazosin 1.8 f 0.32 x 1O-4 
Beta, [3H]dihydroalprenolo1 >10-2 
Displacement experiments were performed with the 
radioligands (& concentrations, approximately) given in 
parentheses as in [19-281. Values presented are the 
means + SE of at least 4 experiments (in triplicates). In- 
hibition constants were calculated according to Ki = 
ZC&(l + LC/&), in which LC is radioligand concen- 
tration, Kd its dissociation constant, and I& the con- 
centration of compound causing 50% inhibition of 
t,, I I I I I I 
11 10 9 8 7 6 5 
-LOGlo DISPLACER [Ml 
Fig. 4. Displacement experiments using [‘Hlnimodipine 
(< 1.5 nM) and nimodipine (NIM), nifedipine (NIF), 
BAY K 8644, and strophanthin. Total binding is plotted 
against -loglo of displacer concentration (M). The 
results demonstrate the high affinity of the binding sites 
for DHP derivatives. Data are the means f SE of 3-5 
experiments using at least 3 different protein prepara- 
tions of rat brain cortices. Dihydropyridine formulae of 
both the potent Ca2+ entry blocker nifedipine (NIF) and 
the Ca2+ channel activating BAY K 8644 are given (in- 
set), and demonstrate the close similarity of these 
chemical structures. Locus of tritiation of [3H]BAY 
‘H-ligand specific binding K 8644 is indicated by an asterisk. 
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occupancy of dihydropyridine receptors by one 
half at 30-40 nM, correlate well with results of the 
functional pharmacology. The, positive inotropic 
action of BAY K 8644 in the perfused heart 
(Langendorff), and the calcium agonistic effect in 
the aortic strip preparation [ 121 were initiated by 1 
nM and exerted maximal effect at about 80-100 
nM of BAY K 8644. 
In summary, the results of the binding 
characteristics reported here support the conclu- 
sion, that both the channel activating and in- 
hibiting dihydropyridine structures interact with 
the same specific receptor site which seems to 
modulate the transmembrane Ca’ + fluxes by 
either inhibiting or enhancing the Cat+ entry via 
putative calcium channels. 
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